Economic value of toripalimab plus axitinib as first-line treatment for advanced renal cell carcinoma in China: a model-based cost-effectiveness analysis.
Shuo KangJintuo YinPublished in: Expert review of pharmacoeconomics & outcomes research (2024)
Toripalimab plus axitinib was unlikely to be the cost-effective first-line therapy for patients with previously untreated advanced RCC compared with sunitinib from the Chinese health-care system perspective.